Epigenetic mechanisms for progression of prostate cancer

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 401-409

  Rennie, Paul S ^a,b   Nelson, Colleen C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JACK BELL RESEARCH CENTRE   (Canada)

Author keywords

Autocrine; DNA methylation; Epigenetic; Histone acetylation; Prostate cancer

Indexed keywords

DNA; GLUTATHIONE TRANSFERASE; GROWTH FACTOR; HISTONE ACETYLTRANSFERASE; SOMATOMEDIN B; STEROID RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; UVOMORULIN;

ACETYLATION; CANCER GROWTH; CANCER INHIBITION; DEACETYLATION; DNA METHYLATION; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0032804575     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006121219097     Document Type: Review

References (76)

1. Riggs AD, Martienssen RA, Russo VEA: Introduction. In: Epigenetic Mechanisms of Gene Regulation. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1996, pp 1-4
2. Mintz B, Illmensee K: Normal genetically mosaic mice produced from malignant teratoma cells. Proc Natl Acad Sci USA 72: 3585-3589, 1975
3. Turker MS, Bestor TH: Formation of methylation patterns in the mammalian genome. Mutat Res 386: 119-130, 1997 Review
4. Jost JP, Bruhat A: The formation of DNA methylation patterns and the silencing of genes. Prog Nucleic Acid Res Mol Biol 57: 217-248, 1997 Review
5. Szyf M: DNA methylation patterns: An additional level of information? Biochem Cell Biol 69: 764-767, 1991
6. Nan X, Campoy FJ, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88: 471-481, 1997
7. Riggs AD, Porter TN: X-chromosome inactivation and epigenetic mechanisms. In: Riggs AD, Martienssen RA, Russo VEA (eds) Epigenetic Mechanisms of Gene Regulation. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1996. pp 231-248
8. Schulz WA: DNA methylation in urological malignancies (review). Int J Oncol 13: 151-167, 1998 Review
9. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 11: 6883-6894, 1983
10. Bedford MT, van Helden PD: Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res 47: 5274-5276, 1987
11. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP: Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48: 880-888, 1991
12. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, Baylin SB: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704, 1994
13. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55: 5195-5199, 1995
14. Reik W, Surani MA: Cancer genetics. Genomic imprinting and embryonal tumours. Nature 338: 112-113, 1989
15. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP: Relaxation of imprinted genes in human cancer. Nature 362: 747-749, 1993
16. Jarrard DF, Bova GS, Isaacs WB: DNA methylation, molecular genetic, and linkage studies in prostate cancer. Prostate 6: 36-44, 1996 Review
17. Paul R, Ewing CM, Jarrard DF, Isaacs WB: The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol 79(Suppl 1): 37-43, 1997 Review
18. Jarrard DF, Paul R, van Bokhoven A, Nguyen SH, Bova GS, Wheelock MJ, Johnson KR, Schalken J, Bussemakers M, Isaacs WB: P-cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer. Clin Cancer Res 3: 2121-2128, 1997
19. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG: Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91: 11733-11737, 1994
20. Brooks JD, Weinstein M, Lin X, Sun Y, Pin SS, Bova GS, Epstein JI, Isaacs WB, Nelson WG: CG island methylation changes near the GSTPI gene in prostatic intraepithelial neoplasia. Canc Epidemiol Biomark Prev 7: 531-536, 1998
21. Nelson JB, Lee WH, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG, Bova GS: Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 57: 35-37, 1997
22. Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG, Isaacs WB: Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Gen Chrom Canc 19: 90-96, 1997
23. Lu S, Tsai SY, Tsai MJ: Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4, and CK1 p16 genes. Cancer Res 57: 4511-4516, 1997
24. Gu K, Mes-Masson AM, Gauthier J, Saad F: Analysis of the p16 tumor suppressor gene in early-stage prostate cancer. Mol Carcinog 21: 164-170, 1998
25. Park DJ, Wilczynski SP, Pham EY, Miller CW, Koeffler HP: Molecular analysis of the INK4 family of genes in prostate carcinomas. J Urol 157: 1995-1999, 1997
26. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95: 5246-5250, 1998
27. Jarrard DF, Bussemakers MJG, Bova GS, Isaacs WB: Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res 1: 1471-1478, 1995
28. Morton RA Jr, Watkins JJ, Bova GS, Wales MM, Baylin SB, Isaacs WB: Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. J Urol 156(2 Pt 1): 512-516, 1996
29. Loidl P: Histone acetylation: Facts and questions. Chromosoma 103: 441-449, 1994 Review
30. Turner BM: Histone acetylation as an epigenetic determinant of long-term transcriptional competence. Cell Mol Life Sci 54: 21-31, 1998 Review
31. Holth LT, Chadee DN, Spencer VA, Samuel SK, Safneck JR, Davie JR: Chromatin, nuclear matrix and the cytoskeleton: Role of cell structure in neoplastic transformation. Int J Oncol 13: 827-837, 1998
32. Thrasher JB, Tennant MK, Twomey PA, Hansberry KL, Wettlaufer JN, Plymate SR: Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: Clinical correlations. J Urol 155: 999-1003, 1996
33. Figueroa JA, De Raad S, Tadlock L, Speights VO, Rinehart JJ: Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 159: 1379-1383, 1998
34. Ho PJ, Baxter RC: Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 46: 333-342, 1997
35. Nishimura A, Fujimoto M, Oguchi S, Fusunyan RD, MacDermott RP, Sanderson IR: Short-chain fatty acids regulate IGF-binding protein secretion by intestinal epithelial cells. Am J Physiol 275(1 Pt 1): E55-63, 1998
36. Rohlff C, Blagoskionny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC: Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate 37: 51-59, 1998
37. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T: Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150, 1997
38. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T: Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272: 22199-22206, 1997
39. Kiermaier A, Eilers M: Transcriptional control: Calling in histone deacetylase. Curr Biol 7: R505-507, 1997 Review
40. Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE: Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89: 341-347, 1997
41. Bernards R: Transcriptional regulation. Flipping the Myc switch. Curr Biol 5: 859-861, 1995 Review
42. Balaji KC, Koul H, Mitra S, Maramag C, Reddy P, Menon M, Malhotra RK, Laxmanan S: Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer. Urology 50: 1007-1015, 1997
43. Hassig CA, Schreiber SL: Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1: 300-308, 1997 Review
44. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ, O'Malley BW: Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389: 194-198, 1997
45. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW: Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279: 1922-1925, 1998
46. Utley RT, Ikeda K, Grant PA, Cote J, Steger DJ, Eberharter A, John S, Workman JL: Transcriptional activators direct histone acetyltransferase complexes to nucleosomes. Nature 394: 498-502, 1998
47. Aarnisalo P, Palvimo JJ, Janne OA: CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci USA 95: 2122-2127, 1998
48. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME: Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCap. J Biol Chem 272: 17485-17494, 1997
49. Frortsdal K, Engedal N, Slagsvold T, Saatcioglu F: CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 273: 31853-31859, 1998
50. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN: Phosphorylation of p53 Serine 15 increases interaction with CBP. J Biol Chem 273: 33048-33053, 1998
51. Luo RX, Postigo AA, Dean DC: Rb interacts with histone deacetylase to repress transcription. Cell 92: 463-473, 1998
52. Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, Chang C: Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem Biophys Res Commun 248: 361-367, 1998
53. Knudsen KE, Arden KC, Cavenee WK: Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 273: 20213-20222, 1998
54. Hassig CA, Tong JK, Schreiber SL: Fiber-derived butyrale and the prevention of colon cancer. Chem Biol 4: 783-789, 1997 Review
55. Perrine GP, Dover GH, Daftari P, Walsh CT, Jin Y, Mays A, Faller D: Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo. Br J Haemato 188: 555-561, 1994
56. Faller DV, Perrine SP: Butyrate in the treatment of sickle cell disease and beta-thalassemia. Curr Opin Hemato 12: 109-117, 1995 Review
57. Grunicke H, Csordas A, Helliger W, Hauptlorenz S, Loidl A, Multhaup I, Zwierzina H, Puschendorf B: Depression of histone acetylation by alkylating antitumor agents: Significance for antitumor activity and possible biological consequences. Adv Enzyme Regul 22: 433-446, 1984
58. Talasz H, Weiss G, Puschendorf B: Replication-linked histone acetylation in rat liver tissue is sensitive to alkylating agents. FEBS Lett 264: 141-144, 1990
59. Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L: Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem 69: 271-281, 1998
60. Isaacs JT, Cussenot O, Jankevicius F, Klocker H, Kubota Y, Morgia G, Rennie P, Schmitz-Drager BJ: Growth regulation of normal and malignant prostatic cells. In: Proceedings of the First International Consultation on Prostate Cancer. Murphy G, Griffiths K, Denis L, Khoury S, Chatelain C, Cockett AT (eds). Scient Com Internat Ltd, 1996, pp 31-81
61. Cohen DW, Simak R, Fair WR, Melamed J, Scher HI, Cordon-Cardo C: Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. 3 Urol 152(6 Pt 1): 2120-2124, 1994
62. Leav I, McNeal JE, Ziar J, Alroy J: The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hyperplastic, dysplastic, and carcinomatous lesions. Hum Pathol 29: 668-675, 1998
63. Dalu A, Haskell JF, Coward L, Lamartiniere CA: Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. Prostate 37: 36-43, 1998
64. Cohen P, Peehl DM, Rosenfeld RG: The IGF axis in the prostate. Horm Metab Res 26: 81-84, 1994 Review
65. Kaicer EK, Blat C, Harel L: IGF-I and IGF-binding proteins: Stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 4: 231-237, 1991
66. Wang YZ, Wong YC: Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 35: 165-177, 1998
67. Li SL, Goko H, Xu ZD, Kimura G, Sun Y, Kawachi MH, Wilson TG, Wilczynski S, Fujita-Yamaguchi Y: Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 291: 469-479, 1998
68. Russell PJ, Bennett S, Stricker P: Growth factor involvement in progression of prostate cancer. Clin Chem 44: 705-723, 1998 Review
69. Russell PJ, Brown J, Grimmond S, Stapleton P, Russell P, Raghavan D, Symonds G: Tumour-induced host stromal-cell transformation: Induction of mouse spindle-cell fibrosarcoma not mediated by gene transfer. Int J Cancer 46: 299-309, 1990
70. Pathak S, Nemeth MA, Multani AS, Thalmann GN, von Eschenbach AC, Chung LW: Can cancer cells transform normal host cells into malignant cells? Br J Cancer 76: 1134-1138, 1997
71. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT: Down-regulation of the KAII metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 56: 4387-4390, 1996
72. Noble RL: Sex steroids as a cause of adenocarcinoma of the dorsal prostate in Nb rats, and their influence on the growth of transplants. Oncology 34: 138-141, 1977
73. Noble RL: The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 37: 1929-1933, 1977
74. Noble RL: Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Res 40: 3547-3550, 1980
75. Pollard M: Dihydrotestosterone prevents spontaneous adenocarcinomas in the prostate-seminal vesicle in aging L-W rats. Prostate 36: 168-171, 1998
76. Bruchovsky N, Goldenberg SL, Gleave M, Rennie P, Akakura K, Sato N: Intermittent therapy for prostate cancer. Endocrine-Rel Canc 4: 153-177, 1997 Review